LivaNova PLC (NASDAQ:LIVN) Stock Has Average Target Price of $87.75

Shares of LivaNova PLC (NASDAQ:LIVN) have been assigned a consensus recommendation of “Moderate Buy” from the eleven research firms that are covering the firm, MarketBeat Ratings reports. Four analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $87.75.

A number of research analysts recently issued reports on LIVN shares. Barclays upgraded LivaNova to a “strong-buy” rating in a research note on Wednesday, October 7th. Mizuho lifted their price target on LivaNova from $90.00 to $95.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 15th. Freedom Capital upgraded LivaNova to a “hold” rating in a research note on Tuesday, June 30th. Needham & Company LLC boosted their price objective on LivaNova from $81.00 to $93.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Finally, Piper Sandler reissued an “overweight” rating and issued a $90.00 price objective (up from $87.00) on shares of LivaNova in a report on Wednesday, September 2nd.

Insider Buying and Selling

In other news, Director Brooke Story sold 2,300 shares of LivaNova stock in a transaction on Friday, September 4th. The shares were sold at an average price of $81.42, for a total value of $187,266.00. Following the transaction, the director directly owned 7,488 shares of the company’s stock, valued at $609,672.96. The trade was a 23.50% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Francesco Bianchi sold 3,500 shares of LivaNova stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $78.01, for a total transaction of $273,035.00. Following the completion of the transaction, the director directly owned 4,434 shares in the company, valued at $345,896.34. The trade was a 44.11% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 7,450 shares of company stock worth $591,839. Insiders own 0.35% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Allworth Financial LP increased its stake in LivaNova by 93.5% in the second quarter. Allworth Financial LP now owns 298 shares of the company’s stock valued at $25,000 after purchasing an additional 144 shares during the period. Farther Finance Advisors LLC raised its holdings in shares of LivaNova by 59.7% in the third quarter. Farther Finance Advisors LLC now owns 452 shares of the company’s stock valued at $35,000 after buying an additional 169 shares during the last quarter. Public Employees Retirement System of Ohio purchased a new stake in shares of LivaNova in the second quarter valued at about $37,000. Integrated Wealth Concepts LLC acquired a new stake in shares of LivaNova during the second quarter worth about $119,000. Finally, EverSource Wealth Advisors LLC boosted its stake in shares of LivaNova by 103.6% during the first quarter. EverSource Wealth Advisors LLC now owns 1,623 shares of the company’s stock worth $103,000 after buying an additional 826 shares during the period. 97.64% of the stock is owned by hedge funds and other institutional investors.

LivaNova Stock Performance

Shares of LIVN stock opened at $76.39 on Friday. The stock’s 50-day moving average is $78.78 and its two-hundred day moving average is $75.10. The firm has a market cap of $4.21 billion, a price-to-earnings ratio of 22.60 and a beta of 0.87. LivaNova has a 1 year low of $48.82 and a 1 year high of $85.76. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.21 and a current ratio of 1.45.

LivaNova (NASDAQ:LIVN) last posted its earnings results on Thursday, August 6th. The company reported $1.26 EPS for the quarter, topping analysts’ consensus estimates of $1.09 by $0.17. LivaNova had a return on equity of 16.35% and a net margin of 12.82%. The business had revenue of $390.59 million for the quarter, compared to analysts’ expectations of $380.50 million. During the same quarter in the previous year, the firm earned $1.05 earnings per share. The business’s revenue was up 10.8% compared to the same quarter last year. Analysts predict that LivaNova will post 3.78 earnings per share for the current year.

LivaNova Company Profile

LivaNova PLC (NASDAQ: LIVN) is a medical device company that develops and markets technologies for the treatment of cardiovascular and neurological conditions. The company’s principal businesses are organized around its Cardiopulmonary and Neuromodulation segments.

Its cardiopulmonary portfolio includes heart-lung machines, oxygenators, perfusion systems and other equipment used during cardiopulmonary bypass procedures, as well as technologies designed to support cardiac surgery and related clinical applications.